Literature DB >> 32304131

Urinary Cyclophilin A and serum Cystatin C as biomarkers for diabetic nephropathy in children with type 1 diabetes.

Nanees Abdel-Badie Salem1, Rania Mostafa El Helaly2, Ibrahim Maroof Ali3, Hala Abd Alem Ebrahim3, Mostafa Mahmoud Alayooti4, Huda Ahmed El Domiaty4, Hadil Mohamed Aboelenin1.   

Abstract

BACKGROUND: Currently, microalbuminuria is the gold standard for detection and prediction of diabetic nephropathy (DN). However, microalbuminuria appears once significant kidney damage has actually occurred.
OBJECTIVES: We investigated the diagnostic role of urinary Cyclophilin-A (uCypA), uCypA/creatinine ratio (uCypA/Cr) and serum Cystatin-C (sCysC) as biomarkers for early detection of DN in children with type 1 diabetes mellitus (T1DM) of short duration (2-5 years) before microalbuminuria emerges.
METHODS: uCypA, uCypA/Cr, and sCysC levels were assessed in three age- and sex-matched groups; microalbuminuric diabetic group (n = 31), normoalbuminuric diabetic group (n = 29), and control group (n = 30). Glomerular filtration rate was estimated (eGFR) based on both serum creatinine (eGFR-Cr) and sCysC (eGFR-CysC).
RESULTS: Significantly higher sCysC and lower eGFR-CysC were detected in both diabetic groups compared to controls and in microalbuminuric compared to normoalbuminuric group. No detected significant difference in eGFR-Cr values across the studied groups. Both uCypA and uCypA/Cr were significantly elevated in microalbuminuric compared to both normoalbuminuric and control groups with no difference between normoalbuminuric and control groups. Prediction of microalbuminuria was conducted using sCysC with area under curve up to 0.980. Combined use of sCysC and uCypA had better diagnostic value than uCypA alone.
CONCLUSION: sCysC is a promising early biomarker for DN in childhood T1DM before albuminuria detection. eGFR-CysC is superior to eGFR-Cr in evaluating renal status in childhood T1DM. uCypA and uCypA/Cr were useful tools in predicting microalbuminuria, although not regarded as diagnostic biomarkers for early-stage DN in T1DM children by the current study.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  diabetic nephropathy; microalbuminuria; serum Cystatin-C; type 1 diabetes mellitus; urinary Cyclophilin-A

Mesh:

Substances:

Year:  2020        PMID: 32304131     DOI: 10.1111/pedi.13019

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  6 in total

Review 1.  Current update on theranostic roles of cyclophilin A in kidney diseases.

Authors:  Sudarat Hadpech; Visith Thongboonkerd
Journal:  Theranostics       Date:  2022-05-13       Impact factor: 11.600

2.  Diagnostic value of serum cystatin C for diabetic nephropathy: a meta-analysis.

Authors:  Xueling Liao; Yan Zhu; Chao Xue
Journal:  BMC Endocr Disord       Date:  2022-06-02       Impact factor: 3.263

3.  Cyclophilin A Promotes Inflammation in Acute Kidney Injury but Not in Renal Fibrosis.

Authors:  Khai Gene Leong; Elyce Ozols; John Kanellis; David J Nikolic-Paterson; Frank Y Ma
Journal:  Int J Mol Sci       Date:  2020-05-22       Impact factor: 5.923

4.  Cystatin C, renal resistance index, and kidney injury molecule-1 are potential early predictors of diabetic kidney disease in children with type 1 diabetes.

Authors:  Ivana Trutin; Zarko Bajic; Daniel Turudic; Andrea Cvitkovic-Roic; Danko Milosevic
Journal:  Front Pediatr       Date:  2022-07-29       Impact factor: 3.569

5.  Calcium dobesilate efficiency in the treatment of diabetic kidney disease through suppressing MAPK and chemokine signaling pathways based on clinical evaluation and network pharmacology.

Authors:  Bingyu Du; Yanyan Yin; Yuqing Wang; Hui Fu; Helin Sun; Zhaodi Yue; Shaohong Yu; Zhongwen Zhang
Journal:  Front Pharmacol       Date:  2022-09-08       Impact factor: 5.988

Review 6.  Diabetic kidney disease in pediatric patients: A current review.

Authors:  Carmen Muntean; Iuliana Magdalena Starcea; Claudia Banescu
Journal:  World J Diabetes       Date:  2022-08-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.